{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:03:07Z","timestamp":1781330587990,"version":"3.54.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1034,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:sec>\n            <jats:title>Key Points<\/jats:title>\n            <jats:p>1. Interferon (IFN) and ribavirin can be used in select patients before or after liver transplantation, and they can reduce the risk of recurrence or effect a cure in these settings.<\/jats:p>\n            <jats:p>2. Currently licensed direct-acting antiviral drugs are used with IFN and ribavirin, so the safety and tolerability of triple therapy will be worse than those of double therapy in pretransplant and posttransplant settings.<\/jats:p>\n            <jats:p>3. Drug-drug interactions [exemplified by the interactions of protease inhibitors (PIs) with tacrolimus and cyclosporine] and the need for dose modifications (exemplified by the need to modify ribavirin doses in patients with renal dysfunction) challenge the safe use of antiviral drugs after transplantation.<\/jats:p>\n            <jats:p>4. Experience with the use of human immunodeficiency virus PIs and emerging data about hepatitis C virus (HCV) PIs show that this class of drugs can be used with care after transplantation.<\/jats:p>\n            <jats:p>5. Attempts to prevent HCV graft infections through the use of HCV immunoglobulin immediately after transplantation have been largely unsuccessful.<\/jats:p>\n            <jats:p>6. The blockade of cell surface HCV receptors with antibodies or small molecules appears to limit HCV cell entry in vivo and in a mouse model, and this may suggest a novel approach to limiting HCV recurrence at the time of transplantation. Liver Transpl, 2012. \u00a9 2012 AASLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.23533","type":"journal-article","created":{"date-parts":[[2012,8,10]],"date-time":"2012-08-10T10:49:53Z","timestamp":1344595793000},"page":"S47-S51","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Understanding the switchbacks: The impact of direct antivirals on the minimization of hepatitis C virus recurrence after transplantation"],"prefix":"10.1097","volume":"18","author":[{"given":"David","family":"Mutimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20250124","doi-asserted-by":"crossref","first-page":"d6972","DOI":"10.1136\/bmj.d6972","article-title":"Protease inhibitors for treatment of genotype 1 hepatitis C virus infection.","volume":"343","author":"Rowe","year":"2011","journal-title":"BMJ"},{"issue":"suppl 2","key":"R2-11-20250124","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(12)60022-1","article-title":"Safety of telaprevir or boceprevir in combination with peginterferon alfaribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20CUPIC) abstract.","volume":"56","author":"Hezode","year":"2012","journal-title":"J Hepatol"},{"key":"R3-11-20250124","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A sustained viral response is associated with reduced liverrelated morbidity and mortality in patients with hepatitis C virus.","volume":"8","author":"Singal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-11-20250124","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jhep.2006.08.020","article-title":"Peginterferon alfa2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.","volume":"46","author":"Iacobellis","year":"2007","journal-title":"J Hepatol"},{"key":"R5-11-20250124","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0168-8278(03)00310-6","article-title":"Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.","volume":"39","author":"Forns","year":"2003","journal-title":"J Hepatol"},{"key":"R6-11-20250124","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2008.11.015","article-title":"Antiviral therapy increases the risk of bacterial infections in HCVinfected cirrhotic patients awaiting liver transplantation: a retrospective study.","volume":"50","author":"Carrion","year":"2009","journal-title":"J Hepatol"},{"key":"R7-11-20250124","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hep.20793","article-title":"Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy.","volume":"42","author":"Everson","year":"2005","journal-title":"Hepatology"},{"key":"R8-11-20250124","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1053\/jlts.2003.50166","article-title":"Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.","volume":"9","author":"Thomas","year":"2003","journal-title":"Liver Transpl"},{"key":"R9-11-20250124","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2036.2009.04025.x","article-title":"Sustained virological responses following standard antiviral therapy in decompensated HCVinfected cirrhotic patients.","volume":"30","author":"Iacobellis","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"suppl 1","key":"R10-11-20250124","doi-asserted-by":"crossref","first-page":"i59i67","DOI":"10.1136\/gutjnl-2012-302076","article-title":"Management of HBV and HCVinduced end stage liver disease.","volume":"61","author":"Mutimer","year":"2012","journal-title":"Gut"},{"issue":"suppl 1","key":"R11-11-20250124","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1478-3231.2011.02714.x","article-title":"Hepatitis C virus treatment pre and postliver transplantation.","volume":"32","author":"Roche","year":"2012","journal-title":"Liver Int"},{"key":"R12-11-20250124","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1111\/j.1600-6143.2005.00976.x","article-title":"Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.","volume":"5","author":"Bizollon","year":"2005","journal-title":"Am J Transplant"},{"key":"R13-11-20250124","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/j.1600-6143.2007.02007.x","article-title":"Immunosuppressant pharmacokinetics and dosing modifications in HIV1 infected liver and kidney transplant recipients.","volume":"7","author":"Frassetto","year":"2007","journal-title":"Am J Transplant"},{"key":"R14-11-20250124","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24443","article-title":"Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.","volume":"54","author":"Garg","year":"2011","journal-title":"Hepatology"},{"key":"R15-11-20250124","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hep.24470","article-title":"Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agentsa potentially lethal cocktail.","volume":"54","author":"Charlton","year":"2011","journal-title":"Hepatology"},{"key":"R16-11-20250124","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/lt.23496","article-title":"Rapid recovery of CYP3A4 following protease inhibitors withdrawal in post liver transplant patients.","volume":"18","author":"Oo","year":"2012","journal-title":"Liver Transpl"},{"issue":"suppl 2","key":"R17-11-20250124","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0168-8278(12)60061-0","article-title":"Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience abstract.","volume":"56","author":"Coilly","year":"2012","journal-title":"J Hepatol"},{"key":"R18-11-20250124","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/lt.23482","article-title":"Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.","volume":"18","author":"Fontana","year":"2012","journal-title":"Liver Transpl"},{"key":"R20-11-20250124","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/lt.20876","article-title":"Monoclonal antibody HCVAbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study.","volume":"12","author":"Schiano","year":"2006","journal-title":"Liver Transpl"},{"key":"R21-11-20250124","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","article-title":"Hepatitis C virus kinetics during and immediately after liver transplantation.","volume":"35","author":"GarciaRetortillo","year":"2002","journal-title":"Hepatology"},{"key":"R22-11-20250124","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/lt.20572","article-title":"Kinetics of hepatitis C virus reinfection after liver transplantation.","volume":"12","author":"Powers","year":"2006","journal-title":"Liver Transpl"},{"key":"R23-11-20250124","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1600-6143.2011.03440.x","article-title":"Characterization of the crossneutralizing antibody response against hepatitis C virus in the liver transplantation setting.","volume":"11","author":"Dragun","year":"2011","journal-title":"Am J Transplant"},{"key":"R24-11-20250124","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1136\/gut.2007.141630","article-title":"Hepatitis C virus entry: possible targets for therapy.","volume":"57","author":"Timpe","year":"2008","journal-title":"Gut"},{"key":"R25-11-20250124","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/hep.22547","article-title":"AntiCD81 antibodies can prevent a hepatitis C virus infection in vivo.","volume":"48","author":"Meuleman","year":"2008","journal-title":"Hepatology"},{"key":"R26-11-20250124","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.24692","article-title":"A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.","volume":"55","author":"Meuleman","year":"2012","journal-title":"Hepatology"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23533","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201211002-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:16:13Z","timestamp":1737738973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201211002-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":25,"journal-issue":{"issue":"Supplement 2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.23533","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}